Electroconvulsive therapy (ECT) is most effective for severe depression, catatonia, and acute psychotic episodes, with response rates ranging from 41% to 100% depending on the condition. It works fastest and most reliably when symptoms are life-threatening or debilitating, and it remains one of the most powerful tools in psychiatry for patients who haven’t responded to medication.
Severe Depression
Depression is the most common reason ECT is used, and the results are strong. A decade-long analysis of national Scottish data found that 73% of patients with moderate to severe depression responded to ECT, and 51% achieved full remission. These numbers are significantly higher than what most antidepressants achieve on their own.
ECT is especially effective when depression includes psychotic features (hallucinations or delusions), melancholic features (complete inability to feel pleasure, severe weight loss, early morning waking), or when the person has stopped eating or drinking. It’s also a first-line option when someone is at high risk of suicide, because it works faster than medication. While antidepressants typically take weeks to show benefit, ECT can begin reducing symptoms within the first few sessions.
For treatment-resistant depression, defined as depression that hasn’t improved after at least two adequate trials of antidepressants, ECT still produces meaningful results. A large trial published in the New England Journal of Medicine found a 41.2% response rate for ECT in this harder-to-treat group. That’s lower than the rates seen in broader depression populations, but notable given that these patients had already failed multiple medications. The same trial compared ECT to ketamine infusions and found ketamine had a higher response rate (55.4%), though both treatments were considered viable options.
Catatonia
Catatonia is where ECT shows its most dramatic results. This severe neuropsychiatric condition causes a person to become immobile, mute, rigid, or unresponsive, sometimes for days or weeks. The first-line treatment is typically a class of anti-anxiety medications, but when those fail, ECT response rates range from 80% to 100% across published studies. No other treatment in psychiatry has comparable success rates.
ECT is considered a first-line treatment (skipping the medication step entirely) in the most dangerous forms: malignant catatonia, where patients develop fever and organ dysfunction that can be fatal, and delirious mania, a state of extreme agitation and confusion. Patients with an underlying mood disorder tend to respond more favorably than those with schizophrenia, and delays in starting ECT appear to reduce its effectiveness. One study at a Dutch teaching hospital found that when ECT was delayed by two months or more after failed medication trials, the response rate dropped to 59%.
Schizophrenia and Psychotic Episodes
ECT is not a standard treatment for schizophrenia on its own, but it plays an important role in specific situations. It’s effective during acute psychotic exacerbations, particularly when a patient is severely agitated, aggressive, or not responding to antipsychotic medications. Clinical guidelines recognize it as appropriate for treatment-resistant schizophrenia and as an add-on to clozapine (the medication typically reserved for the most difficult cases) when clozapine alone isn’t enough.
Postpartum psychosis, a psychiatric emergency that can develop in the days after childbirth, is another recognized indication. ECT can produce rapid improvement in these cases, which matters because the condition poses risks to both parent and infant.
Mania
Severe manic episodes, particularly those involving dangerous agitation, aggression, or mixed features (simultaneous symptoms of mania and depression), respond well to ECT. It’s typically used when the situation requires faster improvement than mood stabilizers can provide, or when standard medications haven’t controlled symptoms. Delirious mania, an especially severe form involving confusion and exhaustion that can become life-threatening, is treated with ECT as a first-line intervention.
Older Adults Respond Faster
ECT tends to work better and faster in older patients. A longitudinal study comparing younger and older adults found that older patients reached remission in a median of 5 sessions compared to 7 for younger patients. Older adults also showed greater improvement in anxiety and physical symptoms of depression. This is particularly relevant because older adults are more likely to have medical conditions that limit which antidepressants they can safely take, making ECT an important alternative.
What a Course of Treatment Looks Like
A standard acute course involves 6 to 12 sessions, given two to three times per week over three to four weeks. The procedure itself takes only a few minutes: you receive general anesthesia and a muscle relaxant, then a brief electrical current is applied to the scalp to induce a controlled seizure lasting about 30 to 60 seconds. You’re unconscious throughout and don’t feel the seizure.
After completing an acute course, the challenge is staying well. Relapse rates without ongoing treatment are high. In one randomized trial, only about 36% of patients on medication alone remained in remission at 12 months. Adding maintenance ECT sessions (given at gradually increasing intervals, such as weekly, then biweekly, then monthly) improved that number to roughly 58%. The combination of maintenance ECT plus medication appears to offer the best protection against relapse, though the benefit narrows somewhat after maintenance sessions stop.
How ECT Affects the Brain
The exact mechanism isn’t fully understood, but several biological changes have been documented. ECT appears to alter the activity of key brain chemicals involved in mood regulation, including serotonin, norepinephrine, and dopamine. It also triggers the release of a protein called brain-derived neurotrophic factor (BDNF), which promotes the growth of new brain cells and new connections between existing ones. Brain imaging studies show that ECT strengthens the wiring between frontal regions (involved in decision-making and emotional regulation) and deeper limbic structures (involved in processing emotions), and the degree of this rewiring correlates with how much a patient improves.
Memory and Cognitive Side Effects
Memory problems are the most discussed side effect and the primary concern for most patients considering ECT. About 60% of patients report some memory issues, with 40% saying these lasted from several weeks to several years. However, when researchers account for the memory problems that depression itself causes, the percentage directly attributable to ECT is lower.
There are two distinct types of memory effects. The ability to form new memories is impaired during and immediately after treatment, but this typically returns to baseline within 4 to 14 days after the final session. The more concerning issue is loss of autobiographical memories, meaning memories of personal experiences from before treatment. These gaps tend to improve significantly by six months, but some lost memories do not return. Studies tracking patients for a year or longer confirm that some autobiographical memory loss persists, and it’s unlikely that memories still missing after 12 months will come back spontaneously.
The severity of memory effects depends on treatment parameters. Bilateral electrode placement (on both sides of the head) causes more memory disruption than right-side-only placement, and higher electrical doses produce more side effects than lower ones. Your treatment team can adjust these variables to balance effectiveness against cognitive risk.
Medical Conditions That Increase Risk
ECT has no absolute contraindications, meaning there is no condition that makes it completely off-limits. But several medical situations significantly increase the risk. A heart attack within the previous four weeks raises the chance of dangerous heart rhythm problems or further cardiac damage, with the risk dropping substantially after three months. Brain aneurysms larger than 1 centimeter carry a risk of rupture during treatment. Blood clots in deep leg veins can potentially dislodge during the seizure and travel to the lungs. Skull defects (from surgery or injury) can allow electrical current to enter the brain directly rather than passing through intact bone.
In each of these cases, ECT isn’t automatically ruled out. The decision comes down to whether the psychiatric condition is dangerous enough to justify the added medical risk, and whether safeguards can be put in place to reduce that risk.